Evotec announced an integrated drug discovery collaboration with STORM Therapeutics to develop new small molecule epigenetic drugs for oncology and other therapeutic areas. The focus will be on a range of newly discovered RNA modulating enzyme targets.
Evotec and STORM have been collaborating since 2016 in high-throughput screening and structural biology to identify hits against two of Storm's RNA modulating targets. The agreement has been expanded to support STORM's chemistry efforts on additional novel targets. Evotec will use its broad drug discovery platform to develop the compounds against these novel RNA targets.
"We are excited to be part of this extended drug discovery collaboration with STORM which is targeting this novel class of RNA modulating enzymes,” Dr. Mario Polywka, Chief Operating Officer of Evotec, said. “This integrated drug discovery collaboration showcases our industry leading drug discovery platform and expertise and shows how it can be applied to the most novel drug targets."